Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enovix Corporation (ENVX) vs GSK plc (GSK) Price & Performance

Enovix CorporationTrade

Price performance (Past 24H)

Key statistics

Enovix Corporation vs GSK plc — how do they compare? Enovix Corporation trades at $4.9 (market cap $1.06B), while GSK plc trades at $50.37 (market cap $102.60B). The key difference: GSK plc is far larger — about 96.8× Enovix Corporation's market cap, and GSK plc pays a 3.57% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.

ENVXGSK
Market Cap
$1.06B$102.60B
Sector
TechnologyHealth
52-Week High
$13.19$61.18
52-Week Low
$3.68$38.22
Enterprise Value
$1.07B$123.04B
Dividend Yield
3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enovix Corporation

ENVX trades at $4.92, up 6.03% in the last 24 hours, with a bullish technical signal despite negative profitability. Recent earnings beats and the appointment of a former Apple executive as COO highlight operational progress. The stock shows strong analyst support with a consensus price target of $12.38, though cash flow remains negative as the company scales production.

Outlook is cautiously optimistic given high growth potential in advanced battery technology, but significant execution risks and persistent losses require careful monitoring. The stock offers upside if production ramps successfully, but volatility may persist near-term.

GSK plc

GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.

Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Enovix Corporation

Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.

Read more on ENVX

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK